Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects higher profits due to an increase in net sales and other factors. The transfer of the marketing authorization for the Yuris drug and the recognition of equity-method investment gains following the designation of アンドファーマ株式会社 as an equity-method affiliate are also expected to contribute.
Loss on disposal and sale of fixed assets: ¥3 million; impairment loss on investment securities: ¥72 million; total extraordinary losses: ¥76 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 126,000 Millions of yen（+7.7%） |
| Operating profit | Not disclosed → 10,500 Millions of yen（+3.5%） |
| Ordinary income | Not disclosed → 12,500 Millions of yen（+11.6%） |
| Profit attributable to owners of the parent | Not disclosed → 10,000 Millions of yen（+26.5%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥116,951 million; operating income: ¥10,147 million; ordinary income: ¥11,195 million; net income attributable to owners of the parent: ¥7,903 million; net income per share: ¥222.96 |
| Reason for the revision | The company expects higher profits due to an increase in net sales and other factors. The transfer of the marketing authorization for the Yuris drug and the recognition of equity-method investment gains following the designation of アンドファーマ株式会社 as an equity-method affiliate are also expected to contribute. |
| Details and amount of extraordinary loss | Loss on disposal and sale of fixed assets: ¥3 million; impairment loss on investment securities: ¥72 million; total extraordinary losses: ¥76 million |
| Dividend forecast revision | For the next fiscal year, the company plans to pay regular dividends of ¥85 per share for the full year, including an interim dividend of ¥42.5 per share. This represents an increase of ¥5 from the current fiscal year's annual dividend of ¥80 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited higher revenue from its pharmaceuticals-related business, primarily driven by growth in new drugs, as well as growth in healthcare products. For the next fiscal year, it expects contributions from the increase in net sales, the transfer of the marketing authorization for the Yuris drug, and the recognition of equity-method investment gains from アンドファーマ株式会社, among other factors.